A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Santa Monica, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Metastatic and /or unresectable disease state after previous standard chemotherapy

Treatment and study plan

ZIO-201

Drug

ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.

Primary outcomes

toxicities

Time frame: 6 months

Secondary outcomes

pharmacokinetics

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Alaunos Therapeutics

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Jan 11, 2007
Registry last updated: Sep 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed